二甲双胍对卵巢癌生存无影响：队列研究的系统评价和荟萃分析。

No Effect of Metformin on Ovarian Cancer Survival: A Systematic Review and Meta-Analysis of Cohort Studies.

机构信息

Department of Preventive Medicine, School of Health Sciences, Wuhan University, No. 185 Donghu Road, Wuhan 430071, China.

Department of Statistics and Management, School of Management, Wuhan Institute of Technology, Wuhan, 430205, China.

出版信息

Curr Pharm Des. 2019;25(23):2595-2601. doi: 10.2174/1381612825666190716113126.

DOI:10.2174/1381612825666190716113126

PMID:31333095

Abstract

BACKGROUND

A number of observational studies examined the association between metformin therapy and ovarian cancer survival outcomes, but the results are inconsistent.

OBJECTIVE

The study aimed to investigate the effect of metformin on survival for ovarian cancer patients.

METHOD

PubMed, Embase and Web of Science databases were searched for relevant studies from the inception to June 11, 2019. The strength of the relationship was assessed using summary of hazard ratios (HRs) with corresponding 95% confidence intervals (CI). Statistical analyses were carried out using the random-effects model.

RESULTS

Totally, 6 retrospective cohort studies involving 2,638 ovarian cancer patients were included. Metformin was not associated with improved overall survival (HR=0.78, 95% CI 0.54-1.12, P=0.175, I2= 61.6%) and disease- free survival (HR=0.49, 95% CI 0.20-1.17, P=0.106, I2=82.1%) in ovarian cancer patients compared to nonmetformin users.

CONCLUSION

The current study provides preliminary evidence that metformin may not be associated with a survival benefit for ovarian cancer patients. More studies with rigorous designs are needed.

摘要

背景

一些观察性研究探讨了二甲双胍治疗与卵巢癌生存结局之间的关系，但结果不一致。

目的

本研究旨在探讨二甲双胍对卵巢癌患者生存的影响。

方法

检索了 PubMed、Embase 和 Web of Science 数据库，从建库到 2019 年 6 月 11 日，检索了相关研究。使用合并风险比（HRs）及其相应的 95%置信区间（CI）评估了关系的强度。使用随机效应模型进行了统计分析。

结果

共纳入 6 项回顾性队列研究，涉及 2638 例卵巢癌患者。与非二甲双胍使用者相比，二甲双胍并未改善卵巢癌患者的总体生存（HR=0.78，95%CI 0.54-1.12，P=0.175，I2=61.6%）和无病生存（HR=0.49，95%CI 0.20-1.17，P=0.106，I2=82.1%）。